Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)

  • End date
    Jul 28, 2024
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 28 October 2022
ct scan
platelet count
total bilirubin
absolute neutrophil count
monoclonal antibodies
systemic therapy
serum pregnancy test
squamous cell carcinoma
lung cancer
serum bilirubin level
neutrophil count
pulmonary fibrosis
cancer treatment
cancer chemotherapy
lung carcinoma


The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.

Condition Non Small Cell Lung Cancer, Lung Cancer, Nsclc, NSCLC Stage II, NSCLC, Stage III
Treatment radiation therapy, durvalumab
Clinical Study IdentifierNCT03999710
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on28 October 2022


Yes No Not Sure

Inclusion Criteria

Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations
Patient age >/= 18 at time of consent
Newly diagnosed or recurrent Locally-advanced NSCLC (stage II-III) amenable for treatment with concurrent definitive radiation and durvalumab
Ineligible for resection and concurrent CRT as determined by one of the following reasons: Medically inoperable, surgically unresectable (including N3 nodal disease), medically unfit or unsafe for chemotherapy, or other reason deemed appropriate by the investigator and approved by PI
Note: The reason a patient is deemed ineligible for concurrent CRT must be documented (i.e
hearing impairment, neuropathy, renal dysfunction, symptomatic/advanced underlying medical
comorbidities, etc.)
Histological and/or cytological confirmation of NSCLC (both squamous and
adenocarcinoma) as per standard of care biopsy; no additional research
protocol-specific biopsy is needed
Candidates for definitive RT to 60 Gy in 30 fractions
Body weight > 30kg
Adequate normal organ and marrow function as defined below
Hemoglobin >/= 9.0 g/dL
Absolute neutrophil count (ANC) 1.5 x (>/= 1500 per mm3)
Platelet count >/= 75 x 10^9/L (>/= 75,000 per mm3)
Serum bilirubin </= 1.5 x institutional upper limit of normal (ULN). This will
not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent
hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis
or hepatic pathology), who will be allowed only in consultation with their
AST (SGOT)/ALT (SGPT) </= 2.5 x institutional upper limit of normal
Measured creatinine clearance (CL) >15mL/min or Calculated creatinine CL>15
mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour
urine collection for determination of creatinine clearance
Creatinine CL (mL/min) = [Weight (kg) x (140 - Age)] / [72 x serum creatinine(mg/dL)]
Creatinine CL (mL/min) = [Weight (kg) x (140 - Age)] / [72 x serum creatinine(mg/dL)] x
Evidence of post-menopausal status or negative urinary or serum pregnancy test for
female pre-menopausal patients. Women will be considered post-menopausal if they have
been amenorrheic for 12 months without an alternative medical cause. The following
age-specific requirements apply
Women >/= 50 years of age would be considered would be considered post-menopausal
if they have been amenorrheic for 12 months following cessation of exogenous
hormonal treatments and if they have luteinizing hormone and follicle-stimulating
hormone levels in the post-menopausal range for the institution or underwent
surgical sterilization (bilateral oophorectomy or hysterectomy)
Women >/= 50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of all exogenous hormonal
treatments, had radiation-induced menopause with last menses > 1 year ago, or
underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy
or hysterectomy)
Patient is willing and able to comply with the protocol for the duration of the study
including undergoing treatment and scheduled visits and examinations including follow
Must have a life expectancy of at least 12 weeks

Exclusion Criteria

Previous thoracic radiation precluding definitive RT
Patients with vitiligo or alopecia
Any chronic skin condition that does not require systemic therapy
Patients with celiac disease controlled by diet alone
Participants in another clinical study with an investigational product during the last
Concurrent enrollment in another clinical study, unless it is an observational
(non-interventional) clinical study or during the follow-up period of an
interventional study
Active or prior documented autoimmune or inflammatory disorders (including
inflammatory bowel disease [e.g., colitis or Crohn's disease], acute diverticulitis
[with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis
syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease
rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to
this criterion
Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
hormone replacement
Patients without active disease in the last 5 years may be included but only
after consultation with the study physician
Any unresolved toxicity NCI CTCAE Grade >/=2 from previous anticancer therapy with the
exception of alopecia, vitiligo, and the laboratory values defined in the inclusion
Patients with Grade >/= neuropathy will be evaluated on a case-by-case basis
after consultation with the Study Physician
Patients with irreversible toxicity not reasonably expected to be exacerbated by
treatment with durvalumab may be included only after consultation with the Study
Prior/Current Therapies
Treatment with a monoclonal antibody within 4 weeks prior to study Day 1 or has
not recovered (i.e., >/= Grade 1 at baseline) from adverse events due to agents
administered > 4 weeks earlier (intraocular bevacizumab is acceptable)
Prior chemotherapy or targeted small molecule therapy, within 3 weeks prior to
study Day 1 or has not recovered (i.e., >/= Grade 1 at baseline) from adverse
events due to a previously administered agents (excluding Grade 2 peripheral
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137
anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLAA-4) antibody, or any other
antibody or drug specifically targeting T-cell co-stimulation or checkpoint
Current or prior use of immunosuppressive medication within 7 days before the
first dose of durvalumab. The following are exceptions to this criterion
i. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
articular injection) ii. Systemic corticosteroids at physiologic doses not to exceed
<<10 mg/day>> of prednisone or its equivalent iii. Steroids as premedication for
hypersensitivity reactions (e.g., CT scan premedication) e. Any concurrent
chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use
of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement
therapy) is acceptable
f. Prior chemotherapy for this diagnosis of lung cancer
Major surgical procedure (as defined by the investigator) within 28 days prior to the
first dose of IP. Note: Local surgery of isolated lesions for palliative intent is
History of allogenic organ transplantation
Severe concurrent illness
Known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trials
Known additional malignancy that is progressing or requires active treatment
Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of
the skin, or in situ cervical cancer that has undergone potentially curative
Active known infection including tuberculosis (clinical evaluation that includes
clinical history, physical examination and radiographic findings, and TB testing
in line with local practice) or hepatitis B (known positive HBV surface antigen
(HBsAg) result). Patients with a past or resolved HBV infection (defined as the
presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are
eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if
polymerase chain reaction is negative for HCV RNA. Testing for Hepatitis C and
HIV is not required unless clinically indicated
Evidence of interstitial lung disease or active, non-infectious pneumonitis
Clinically significant (i.e., active) cardiovascular disease: symptomatic
cerebral vascular accident/stroke (< 6 months prior to enrollment) with out
neurological recovery, unstable angina, congestive heart failure (≥ New York
Heart Association Classification Class III), or serious cardiac arrhythmia
uncontrolled with current medication
Female patients who are pregnant or breastfeeding or male or female patients of
reproductive potential who are not willing to employ a highly effective birth control
from screening to 90 days after the last dose of durvalumab monotherapy
a. Highly effective methods of contraception, defined as one that results in a low
failure rate (ie, less than 1% per year) when used consistently and correctly are
described in Table 1. Note that some contraception methods are not considered highly
effective (e.g. male or female condom with or without spermicide; female cap
diaphragm, or sponge with or without spermicide; non-copper containing intrauterine
device; progestogen-only oral hormonal contraceptive pills where inhibition of
ovulation is not the primary mode of action [excluding Cerazette/desogestrel which is
considered highly effective]; and triphasic combined oral contraceptive pills)
i. Barrier/Intrauterine Methods: Copper T intrauterine device
Levonorgestrel-releasing intrauterine system (e.g., Mirena) ii. Hormonal Methods
Implants - Etonogestrel-releasing implants (e.g. Implanon or Norplant); Intravaginal -
Ethinylestradiol/etonogestrel-releasing intravaginal devices (e.g., NuvaRing)
Injection - Medroxyprogesterone (e.g., Depo-Provera); Combined Pill - normal and low
dose combined oral contraceptive pill; Patch -
Norelgestromin/ethinylestradiol-releasing transdermal system (e.g., Ortho Evra)
Minipills: Progesterone based oral contraceptive pill using desogestrel (Cerazette is
currently the only highly effective progesterone-based)
Live vaccination with 4 weeks prior to the first dose of durvalumab and while on trial
is prohibited except for administration of inactivated vaccines
Connective tissue disorders involving the lung(s) and/or esophagus requiring active
treatment or idiopathic pulmonary fibrosis
Known actionable EGFR or ALK mutation
Known contraindications to radiotherapy
Known allergy or hypersensitivity to any of the study drugs or any of the study drug
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note